COMMUNIQUÉS West-GlobeNewswire

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for AVMAPKI™FAKZYNJA™ CO-PACK
12/05/2025
LOUISVILLE, Ky., May 12, 2025 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Verastem Oncology for AVMAPKI ™ FAKZYNJA ™ CO-PACK ( [...]
LifeMD to Participate in Three Investor Conferences During May
12/05/2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences [...]
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
12/05/2025
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments Raised gross proceeds of ~$20 [...]
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
12/05/2025
Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC Expansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma patients with EGFR [...]
Maravai Lifesciences Reports First Quarter 2025 Financial Results
12/05/2025
SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today [...]
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Sup porting Potential Best-in- [...]
ProKidney Reports First Quarter 2025 Financial Results and Business Highlights
12/05/2025
Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025 FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional details on [...]
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual [...]
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones
12/05/2025
FDA Breakthrough Device Designation Awarded to AVIM Therapy FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch NEW HOPE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “ [...]
Editas Medicine Announces First Quarter 2025 Results and Business Updates
12/05/2025
Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week [...]
Vireo Growth Inc. Announces Closing of WholesomeCo Cannabis & Arches Merger Transactions
12/05/2025
– Acquisitions strengthen profitability and competitive position with proprietary technology platform – – Missouri and Nevada transactions remain on track to close during the second quarter of 2025 – MINNEAPOLIS, May 12 [...]
Cellectis Reports Financial Results for the First Quarter 2025
12/05/2025
Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025 Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing [...]
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
12/05/2025
MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), [...]
Cellectis publie ses résultats financiers du premier trimestre 2025
12/05/2025
Lasmé-cel (UCART22) : présentation des données de Phase 1 et de la stratégie de développement avancé prévue au troisième trimestre 2025 Éti-cel (UCART20x22) : essai clinique de Phase 1 en cours dans le lymphome non [...]
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights
12/05/2025
FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced positive [...]
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
12/05/2025
Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapy SEED’s first‑in‑class RBM39 degrader, reported at AACR 2025 for [...]
ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress
12/05/2025
KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator TM VAR 200 in patients with diabetic kidney disease (DKD). Obesity- [...]
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/05/2025
PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid [...]
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
12/05/2025
COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH ( [...]

Pages